Lupus nephritis (LN) is an autoimmune disease which affects approximately 40–70% of patients with Systemic Lupus Erythematosus (SLE) and is the leading cause of morbidity and mortality in SLE. LN causes the body’s immune system to attack the kidneys, which leads to flares of kidney inflammation. Avoiding kidney function deterioration presents a significant area of unmet need in LN management, because existing tools are ineffective.
But what if there was a biomarker that could detect kidney inflammation in body fluids? Clinical studies show that the level of LGALS3BP (Lectin Galactoside-Binding Soluble 3 Binding Protein) in urine correlates with other active disease markers, such as clinical symptoms of kidney inflammation. It also shows a moderate correlation with the renal disease activity index, as currently used in LN monitoring. Building on these findings, Merck has succeeded in developing a RUO (Research Use Only) kit that allows quantitative analysis of LGALS3BP in urine.
We now invite scientists to test the potential of this new biomarker for LN related kidney inflammation: Our novel sandwich ELISA kit for LGALS3BP using in-house developed monoclonal antibodies is now available as a custom assay for research use.
Click here to request a quote using the “Request information button”. Or contact your local MilliporeSigma representative and request a quote for custom kit SPRCUS86.
We are curious to learn about your findings and encourage you to publish and share your results with the LN research community.
To access the latest research in LN regarding the LGALS3BP biomarker, send us an email at email@example.com – we will be happy to share the following posters with you: